Key result
Cell therapy yields modest clinical benefits in cardiac repair, spurring research into optimized delivery and preconditioning.
Why the study?
Cell therapy for myocardial infarction or heart failure has shown modest benefits with limitations that require strategies to enhance therapeutic efficacy.
This review summarizes current challenges in cardiac cell therapy and outlines strategies such as alternative cell sources and improved delivery mechanisms to enhance therapeutic outcomes.
Answers are grounded in this paper and cite their sources.
Should not yet change clinical practice; leaves open optimization of cell sources, delivery, and preconditioning.
C ell therapy has emerged as a promising option to treat myocardial infarction or heart failure; more than 1500 patients with cardiovascular diseases are treated with adult progenitor cells worldwide. The treatment of acute and chronic myocardial infarction with adult bone marrowderived cells provided a modest benefit in most but not all studies. A number of plausible reasons have been discussed to explain the modest effects, sending researchers back to the bench to elucidate strategies to overcome the limitations of cell therapy and to develop more efficient approaches. Such strategies include the use of other sources to isolate adult progenitor cells (eg, adipose or cardiac tissue) or the generation of pluripotent cells by the reprogramming of somatic cell types. Successful cardiac cell therapy in clinical practice also depends on the efficient delivery and the appropriate integration and alignment of injected or infused cells. The pretreatment of cells with activators to augment cell homing and survival or the improvement of cell delivery tools may provide an opportunity to increase the number of active cells in ischemic or diseased tissues, thereby increasing their therapeutic potential. Finally, the identification of molecules guiding cardiac differentiation provides novel tools to enforce the formation of new functionally active cardiomyocytes to augment cardiac regeneration in its pure sense.
No takes yet. Share an insight, caveat, or question.
Chavakis et al. (2010) conducted a review in Myocardial infarction or heart failure. Cell therapy was evaluated. Cell therapy for cardiac repair has shown modest clinical benefits, prompting research into alternative cell sources, improved delivery methods, and cell preconditioning to enhance therapeutic efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: